<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04213287</url>
  </required_header>
  <id_info>
    <org_study_id>70/13</org_study_id>
    <nct_id>NCT04213287</nct_id>
  </id_info>
  <brief_title>Multimodal Analgesia Methods in Patients Undergoing IPACK Block in Knee Arthroplasty</brief_title>
  <official_title>Evaluation of Multimodal Analgesia Methods in Patients Who Underwent IPACK Block in Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara Diskapi Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankara Diskapi Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of two pain control methods - the combination of Adductor Canal Block
      (ACB)/Infiltration of the interspace between the popliteal artery and the capsule of the
      posterior knee (IPACK) versus the Periarticular Injection (PAI)/ Infiltration of the
      interspace between the popliteal artery and the capsule of the posterior knee (IPACK) - in
      patients undergoing total knee arthroplasty. dexketoprofen and paracetamol will be added to
      both groups and multimodal analgesia will be applied. Primary outcome is NRS pain scores with
      ambulation on postoperative day one (24 hours post-block administration).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative pain after total knee arthroplasty is serious and difficult to management.
      Multimodal analgesia recommended for the pain management. For these reasons, we planned a
      study involving two multimodal analgesia regimens. Patients who will undergo total knee
      arthroplasty will receive preemptive oral analgesic (dexketofrofen) 1 hour before the
      operation. Surgery will be initiated after spinal anesthesia is applied to the patients. Two
      pain control methods - the combination of Adductor Canal Block (ACB)/Infiltration of the
      interspace between the popliteal artery and the capsule of the posterior knee (IPACK) versus
      the Periarticular Injection (PAI)/ IPACK- will be applied at the end of the surgery.
      dexketoprofenand paracetamol will be added to both groups and multimodal analgesia will be
      applied. Primary outcome is NRS pain scores with ambulation on postoperative day one (24
      hours post-block administration).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Power analysis will be done after a pilot study. Number of patient may vary.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NRS Pain Scores</measure>
    <time_frame>24 hours post block administration</time_frame>
    <description>NRS Pain scores with ambulation 24 hours post block administration.All patients' postoperative pain numerical rating scale (NRS-numeric rating scale; 0 = absence of pain, 10 = unbearable pain) will be recorded in both groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS at Rest and with movement</measure>
    <time_frame>24 hours on Post-Operative Day 1</time_frame>
    <description>NRS at rest and with movement at different intervals. All patients' postoperative pain numerical rating scale (NRS-numeric rating scale; 0 = absence of pain, 10 = unbearable pain) will be recorded in both groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction with Pain Control using the likert scale</measure>
    <time_frame>Post-Operative 24 hours</time_frame>
    <description>Satisfaction with Pain control at different intervals. 1-5 (according to patient satisfaction)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>IPACK Block Multimodal Analgesia</condition>
  <condition>Postoperative NRS Scores</condition>
  <arm_group>
    <arm_group_label>Peri-Articular Injections and IPACK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine
At the end of surgery;
PAI: 30 ml 0,025% bupivacaine and
IPACK: 20 ml 0,025% bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adductor Canal Block, and IPACK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spinal anesthetic with 2,5 ml 0,5% heavy bupivacaine
At the end of surgery;
ADD: 20 ml 0,025% bupivacaine and
IPACK: 20 ml 0,025% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen Trometamol</intervention_name>
    <description>Drug: Dexketoprofen Trometamol oral tablet</description>
    <arm_group_label>Adductor Canal Block, and IPACK</arm_group_label>
    <arm_group_label>Peri-Articular Injections and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>spinal anesthesia</intervention_name>
    <description>Drug: heavy bupivacaine 2,5 ml 0,5%</description>
    <arm_group_label>Adductor Canal Block, and IPACK</arm_group_label>
    <arm_group_label>Peri-Articular Injections and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IPACK</intervention_name>
    <description>Drug: bupivacaine 20 ml 0,025%</description>
    <arm_group_label>Adductor Canal Block, and IPACK</arm_group_label>
    <arm_group_label>Peri-Articular Injections and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PAI</intervention_name>
    <description>Drug: bupivacaine 30 ml 0,025%</description>
    <arm_group_label>Peri-Articular Injections and IPACK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adductor canal block</intervention_name>
    <description>Drug: bupivacaine 20 ml 0,025%</description>
    <arm_group_label>Adductor Canal Block, and IPACK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with osteoarthritis scheduled for a primary either partial or total knee
             arthroplasty with a participating surgeon

          -  Age 18 to 80 years

          -  Planned use of regional anesthesia

          -  Ability to follow study protocol

          -  Patients of participating surgeons

        Exclusion Criteria:

          -  Hepatic or renal insufficiency

          -  Younger than 18 years old and older than 80

          -  Patients undergoing general anesthesia

          -  Allergy or intolerance to one of the study medications

          -  BMI &gt; 40

          -  Diabetes

          -  ASA of IV

          -  Chronic gabapentin/pregabalin use (regular use for longer than 3 months)

          -  Chronic opioid use (taking opioids for longer than 3 months, or daily oral morphine
             equivalent of &gt;5mg/day for one month)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilkay MD Baran Akkuş, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diskapi Yildirim Beyazit Training Education Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ilkay MD Baran akkus, MD</last_name>
    <phone>0905323852642</phone>
    <phone_ext>0903125902000</phone_ext>
    <email>ilkayb@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diskapi Yildirim Beyazit Training Research Hospital</name>
      <address>
        <city>Ankara</city>
        <state>Altındag</state>
        <zip>06450</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ilkay baran, md</last_name>
      <phone>5323852642</phone>
      <email>ilkayb@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2019</study_first_posted>
  <last_update_submitted>December 25, 2019</last_update_submitted>
  <last_update_submitted_qc>December 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara Diskapi Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>ilkay baran akkuş</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexketoprofen trometamol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

